Disrupting the p53-mdm2 interaction as a potential therapeutic modality

Ute M. Moll, Alex Zaika

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

P53 and mdm2 are linked to each other through a negative feedback loop. P53 transactivates mdm2, but mdm2, in turn, is a major opponent of p53. Mdm2 promotes p53 degradation through a ubiquitin-dependent pathway on 26S proteasomes and is thought to be largely responsible for the very low levels of p53 protein in unstressed cells. The rationale for targeting the p53-mdm2 interaction therapeutically lies in the ability to activate p53 in all those tumors that retain wild type p53. (C) 2000 Harcourt Publishers Ltd.

Original languageEnglish (US)
Pages (from-to)217-221
Number of pages5
JournalDrug Resistance Updates
Volume3
Issue number4
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Cancer Research
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Disrupting the p53-mdm2 interaction as a potential therapeutic modality'. Together they form a unique fingerprint.

  • Cite this